[Photo by Yonhap]
The Korean Intellectual Property Office (KIPO) said on Thursday it has filed a lawsuit to nullify patent protection of Daewoong Pharmaceutical’s gastrointestinal disease treatment after some test data of the drug were found falsified.
The patent office also requested prosecution to investigate the pharmaceutical company on charges of violating the patent law.
The lawsuit filing follows a KIPO examiner’s judgment that Daewoong Pharmaceutical had fabricated most of experimental data on pharmacological effects, which were essential for drug-related patents.
Daewoong Pharmaceutical obtained composition patent for the drug in January 2016.
Last month, the country’s Fair Trade Commission (FTC) said that Daewoong Pharmaceutical is suspected of having filed a patent lawsuit against a competitor after acquiring a patent by manipulating data, which is an unfair transaction, levying a fine of 2.3 billion won ($2.07 million). The FTC also brought a criminal complaint against the company to prosecution on the violation of the fair trade law.
The FTC said that the investigation led by the Ministry of Food and Drug Safety found Daewoong Pharmaceutical had inflated success data related to bioequivalence tests in the patent specification and manipulated some figures.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]